A Registry Study on Serumal Biomarkers About Adverse Events in Patients Undergoing Coronary Artery Bypass Grafting.

Cardiac Surgery Clinical Trial

— ASBA-CABG  

Official title:

A Chinese Registry to Determine the Serumal Biomarkers for Prognosis of Adverse Events in Patients Undergoing Coronary Artery Bypass Grafting.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04107571
• Other study ID #: 20190924
• Status: Recruiting
• Start date: January 1, 2019
• Est. completion date: June 2024

Study information

• Verified date: September 2019
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: Yulin Li, PHD
• Phone: 86-010-64426153
• Email: lyllyl_1111[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a national registry study to determine the serumal biomarkers for prognosis of adverse events in patients undergoing coronary artery bypass grafting.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: June 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject undergoing coronary artery bypass grafting;

2. Age is more than 18 and less than 80 years old;

3. Male and non pregnancy female;

4. Subject who understands study requirements and agrees to sign an informed consent from prior to study procedures.

Exclusion Criteria:

1. Pregnancy female;

2. Participate in other clinical trial in the last 1 month.

3. Subject who doesn't agree to sign an informed consent from prior to study procedures.

4. Subject undergoing repeat CABG, concomitant valve or other cardiac surgery.

Related Conditions & MeSH terms

• Cardiac Surgery

Intervention

Procedure:
• A type of operation for coranary heart disease patients.
A type of operation for coranary heart disease patients.

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause death and cardiac death		These data is collected during follow-up visit at in-hospital/1 year after discharge
Secondary	Major adverse cardiac events (MACE)	A composite of death, myocardial infarction, stroke, heart failure, ventricular arrhythmia	These data is collected during follow-up visit at in-hospital/1 year after discharge